LakeShore Biopharma Co., Ltd (LSB) — Net Asset Quality Index
LakeShore Biopharma Co., Ltd (LSB) has a Net Asset Quality Index of 36.5% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $1.37 Billion minus total liabilities of $867.91 Million yields net assets of $499.75 Million. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can LakeShore Biopharma Co., Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
LakeShore Biopharma Co., Ltd Net Asset Quality Index Over Time (2021–2025)
This chart shows how LakeShore Biopharma Co., Ltd's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of June 2025, the index stands at 36.5%, representing net assets of $499.75 Million against total assets of $1.37 Billion USD. Explore LakeShore Biopharma Co., Ltd operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for LakeShore Biopharma Co., Ltd (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for LakeShore Biopharma Co., Ltd from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is LakeShore Biopharma Co., Ltd worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 36.5% | $499.75 Million | $1.37 Billion | $867.91 Million | ▼ -2.1 pp |
| 2024 | 38.7% | $585.21 Million | $1.51 Billion | $927.82 Million | ▼ -3.7 pp |
| 2023 | 42.4% | $728.45 Million | $1.72 Billion | $991.30 Million | ▼ -47.5 pp |
| 2022 | 89.9% | $180.68 Million | $201.03 Million | $20.35 Million | ▲ +66.5 pp |
| 2021 | 23.4% | $21.36K | $91.37K | $70.01K | — |